Greenwich LifeSciences Inc
GLSI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$255.55M
Close$
$0.46
97.2% downside
Current Fair Value
97.2% downsideOvervalued by 97.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $255.55 Million |
|---|---|
| Enterprise Value | $246.67 Million |
| Earnings per Share | $-1.43 |
| Beta | 1.46 |
| Outstanding Shares | 14,621,230 |
Return
| Return on Equity | -695.56% |
|---|---|
| Return on Assets | -244.25% |
| Return on Invested Capital | -699.21% |
Valuation & Multiples
| P/E Ratio | -11.31 |
|---|---|
| PEG | 594.06 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 69328.63 |
| Enterprise Value to EBIT | -11.32 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.34
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.30
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.24%▼ 11.42% |
|---|---|
| Total Invested | $627,383▼ 98.43% |
| Investors Holding | 3▼ 57.00% |
About Greenwich LifeSciences Inc
2 employees
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transm...